If we all work together, we can improve #HepatitisC testing and treatment programs around the world. Learn about our commitment to advancing care in the global #HCV community and help eliminate the disease by 2030 in our article with POLITICO Studio: https://politi.co/3AXfhgg [Video description: Mudra Kapoor, M.D., VP, Global Medical Affairs, Specialty & Global Medical Operations, AbbVie, says, “The WHO’s goal to eliminate HCV by 2030 is extremely motivational, but more needs to be done. Without patients getting screened and treated, we won't eliminate this disease – something we have the tools to do and is in our grasp.”]
AbbVie
Fabricación de productos farmacéuticos
North Chicago, Illinois 1.414.344 seguidores
Sobre nosotros
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. AbbVie employs approximately 26,000+ people worldwide and markets medicines in more than 170+ countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter and like us on Facebook.
- Sitio web
-
http://www.abbvie.com
Enlace externo para AbbVie
- Sector
- Fabricación de productos farmacéuticos
- Tamaño de la empresa
- Más de 10.001 empleados
- Sede
- North Chicago, Illinois
- Tipo
- Empresa pública
- Especialidades
- Biopharmaceutical, Biotechnology, Innovation, Research and Development, Manufacturing, Biotherapeutics, Oncology, Immunology, Virology, Neuroscience, Womens Health, Aesthetics y Eye Care
Ubicaciones
Empleados en AbbVie
Actualizaciones
-
JUST IN: New data showcasing progress from our ADC program will be presented at #ESMO24. Learn more about the advancement of our #SolidTumors R&D in tumor types with high unmet needs: https://bit.ly/3AQFVas [Video description: On-screen text reads, “Oncology News.”]
-
Early diagnosis and care are important for people living with #migraine. Through research, we have a deep understanding of the science behind migraine and the impact it can have. Learn more about the reality of living with migraine: https://bit.ly/4ebIDps #MTIS2024 [Video description: AbbVie employees share when they first were impacted by migraine attacks.]
-
The longtime standards of #BloodCancer treatment have greatly evolved over the past decade – and our #scientists see even more possibilities ahead. Learn why: https://bit.ly/4edC8CI #BloodCancerAwarenessMonth [Video description: Animation of cells and a scientist. On-screen text reads, "Oncology research is in a renaissance. In less than 30 years, survival rates have nearly doubled for some blood cancers. And tomorrow’s treatments can help take us even further. See what scientists are working on next."]
-
Yesterday we recognized Global #TalentAcquisition Day and our TA teams worldwide working to bring the best and brightest talents to our organization. Their efforts are instrumental in fostering our culture and creating an inclusive global workforce that drives progress and success. #GlobalTADay #AbbVieLife [Video description: AbbVie employees share what do they love about working in Talent Acquisition.]
-
During #BloodCancerAwarenessMonth, we’re continuing to spark dialogue on policy solutions to help enable equitable access to #BloodCancer treatments – stemming from the report we published with IQVIA. Join us on Sept. 17 for a symposium on addressing global challenges to improve access to innovative hematology therapies. Register now: https://bit.ly/4goDNHs [Video description: Illustrations depicting a researcher in a lab, a patient receiving care and a group of people interacting. On-screen text: “Researchers have discovered multiple new therapies to treat blood cancers, creating new possibilities for patients. Yet some patients must wait years to receive these innovative treatments. We must ensure that health systems around the world are set up to provide efficient and equitable access to hematology therapies.”]
-
In partnership with Acute Leukemia Advocates Network we support patients and caregivers as they navigate life with #AML. Watch the latest episode of our “Blood Cancer, Explained” series to hear more: https://bit.ly/3MvGdpN [Video description: Samantha Nier, Network Director of Acute Leukemia Advocates Network, discusses reiterating the availability of resources to patients and caregivers throughout the AML care journey.]
-
#Migraine is a debilitating neurological disease. Through our research and connection with the patient community, we have a deep understanding of the burden and its daily impact. Join us in helping elevate these patients' voices and bringing awareness to the severity of this disease. Hear more from our own employees living with migraine: https://bit.ly/3z4uz23 [Video description: AbbVie employees living with migraine share how the company supports them.]
-
This World #CLL Awareness Day, we’re highlighting opportunities to help address the unmet needs of people touched by CLL globally. Stay tuned for our global CLL impact report to be shared later this year, which will provide a closer look at how CLL affects global communities. #WCLLD24 [Image description: On-screen text reads, “Many patients report that the emotional journey of CLL begins at diagnosis. It can feel more insurmountable than the physical effects of the disease at times. That’s one of the reasons why AbbVie is exploring the emotional impact of CLL in our upcoming global report. Stay tuned for our full global report coming later this year.”]
-
Today, we’re celebrating #WomensEqualityDay by recognizing the powerful contributions of the women in our organization. Their impact is felt throughout our workplace and in the communities where we work and live. #BelongAtAbbVie [Video description: An animated photo collage of women at AbbVie. On-screen text reads, "Happy Women's Equality Day to all the women helping us make a remarkable impact."]
Páginas asociadas
Páginas similares
Acciones
ABBV
NYSE
20 minutos de retraso
196,42 US$
3,02 (1,562 %)
- Apertura
- 194,97
- Mínimo
- 193,94
- Máximo
- 196,61
Datos de Refinitiv
Consulta más información enFinanciación
Última ronda
Deuda tras OPV15.000.000.000,00 US$